Results 11 to 20 of about 1,848 (184)

Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension

ERJ Open Research, 2023
Further understanding of when to initiate therapies in pulmonary arterial hypertension (PAH) is important to improve long-term outcomes. Post hoc analyses of GRIPHON (NCT01106014) and exploratory analyses of TRITON (NCT02558231) suggested benefit of ...
J. Gerry Coghlan, Sean Gaine, Richard Channick, Kelly M. Chin, Camille du Roure, J. Simon R. Gibbs, Marius M. Hoeper, Irene M. Lang, Stephen C. Mathai, Vallerie V. McLaughlin, Lada Mitchell, Gérald Simonneau, Olivier Sitbon, Victor F. Tapson, Nazzareno Galiè   +14 more
doaj   +3 more sources

Baseline history of patients using selexipag for pulmonary arterial hypertension

Therapeutic Advances in Respiratory Disease, 2019
Introduction: Since its introduction to the market in 2016, selexipag has been an alternative oral therapy among both treatment-naïve patients and those with mono or dual therapy failure; however, limited information is available regarding the ...
Kristin B. Highland, Michael Hull, Janis Pruett, Caitlin Elliott, Yuen Tsang, William Drake   +5 more
doaj   +2 more sources

A Canadian, retrospective, multicenter experience with selexipag for a heterogeneous group of pediatric pulmonary hypertension patients

Frontiers in Pediatrics, 2023
IntroductionSelexipag, an oral nonprostanoid prostaglandin receptor agonist, has led to reduced morbidity and mortality in adults with pulmonary arterial hypertension (PAH). While the adult literature has been extrapolated to suggest selexipag as an oral
David Youssef, Susan Richards, Sabine Lague, Catherine Sheppard, Jenna Smith, Erika Vorhies, Martin Hosking, Matthew Pietrosanu, Angela Bates, Angela Bates   +9 more
doaj   +3 more sources

Selexipag for the Treatment of Pulmonary Arterial Hypertension [PDF]

New England Journal of Medicine, 2015
In a phase 2 trial, selexipag, an oral selective IP prostacyclin-receptor agonist, was shown to be beneficial in the treatment of pulmonary arterial hypertension.In this event-driven, phase 3, randomized, double-blind, placebo-controlled trial, we randomly assigned 1156 patients with pulmonary arterial hypertension to receive placebo or selexipag in ...
Sitbon, Olivier, Channick, Richard, Chin, Kelly M., Frey, Aline, Gaine, Sean, Galiè, Nazzareno, Ghofrani, Hossein-Ardeschir, Hoeper, Marius M., Lang, Irene M., Preiss, Ralph, Rubin, Lewis J., Di Scala, Lilla, Tapson, Victor, Adzerikho, Igor, Liu, Jinming, Moiseeva, Olga, Zeng, Xiaofeng, Simonneau, Gérald, McLaughlin, Vallerie V., GRIPHON Investigators   +19 more
openaire   +6 more sources

Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag:  a case report  [PDF]

Journal of Medical Case Reports, 2022
Background Pulmonary arterial hypertension is a progressive, debilitating condition characterized by increased resistance in the pulmonary arterial circulation.
Mariangela Lattanzio, Marco Ferrari, Stefano Martini, Francesca Ceriani, Andrea Imporzani, Franca Marino, Roberto De Ponti, Marco Cosentino   +7 more
doaj   +2 more sources

Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report [PDF]

ESC Heart Failure, 2023
Intravenous (i.v.) prostacyclin is the cornerstone treatment in high‐risk pulmonary arterial hypertension (PAH) patients. Selexipag is an orally available prostacyclin receptor agonist.
André Alexandre, Inês Furtado, Luísa Carvalho, Fabienne Gonçalves, Alzira Melo, Joana Alves, Mário Santos, Abílio Reis   +7 more
doaj   +2 more sources

The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.

PLoS ONE, 2020
Pulmonary arterial hypertension (PAH) is a lethal disease characterized by a progressive increase in pulmonary artery pressure due to an increase in vessel tone and occlusion of vessels. The endogenous vasodilator prostacyclin and its analogs are used as
Yohei Honda, Keiji Kosugi, Chiaki Fuchikami, Kazuya Kuramoto, Yuki Numakura, Keiichi Kuwano   +5 more
doaj   +2 more sources

The Role of Intravenous Selexipag in Managing PAH and Bridging Gaps in Oral Treatment: A Narrative Review [PDF]

Therapeutics and Clinical Risk Management
Sienna Goren,1,* Nermeen Kidwai,1,* Wilbert S Aronow,2 Gregg M Lanier2 1New York Medical College, Valhalla, NY, USA; 2Departments of Medicine and Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA*These authors ...
Goren S, Kidwai N, Aronow WS, Lanier GM
doaj   +3 more sources

Selexipag in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH‐CTD): Real‐world experience from EXPOSURE

Pulmonary Circulation
Selexipag is indicated for the treatment of pulmonary arterial hypertension (PAH), including PAH associated with connective tissue disease (CTD), and further insights into the management of selexipag‐treated PAH‐CTD patients in clinical settings are ...
Sean Gaine, Pilar Escribano‐Subias, Audrey Muller, Catarina C. Fernandes, Martina Fontana, Tatiana Remenova, Stefan Söderberg, Tobias J. Lange   +7 more
doaj   +2 more sources

Hospitalization Among Pulmonary Arterial Hypertension Patients With and Without Connective Tissue Disease Comorbidities Prescribed Oral Selexipag

Rheumatology and Therapy, 2023
Introduction Patients with connective tissue disorders (CTD) and pulmonary arterial hypertension (PAH) have a poorer prognosis than those with other PAH etiologies.
Yuen Tsang, Risho Singh, Sumit Verma, Sumeet Panjabi   +3 more
doaj   +2 more sources